Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (J.P.) jplutzky@bwh.harvard.edu.
² Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Medicine, IL (G.B.).

Editorial

Jorge Plutzky et al. Circulation. 2018.

. 2018 Jan 9;137(2):130-133.

doi: 10.1161/CIRCULATIONAHA.117.031422.

¹ Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (J.P.) jplutzky@bwh.harvard.edu.
² Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Medicine, IL (G.B.).

No abstract available

Keywords: Editorials; cardiovascular diseases; diabetes mellitus; kidney diseases.

Comment on

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13. Circulation. 2018. PMID: 28904068 Clinical Trial.